Srikanth Singamsetty is experienced in academic and biopharma industry drug development programs. His most recent positions are at the University of North Carolina Catalyst for Rare Diseases (gene therapy programs) and Charles River Laboratories Discovery and Safety Assessment group.
September, 2021 - present